Suppr超能文献

一种主要由高水溶性有机酸组成的片剂肠溶包衣配方及工艺的开发。

Development of an enteric coating formulation and process for tablets primarily composed of a highly water-soluble, organic acid.

作者信息

Crotts G, Sheth A, Twist J, Ghebre-Sellassie I

机构信息

Pharmaceutical Research and Development, Pfizer Global Research and Development, NJ, Morris Plains, USA.

出版信息

Eur J Pharm Biopharm. 2001 Jan;51(1):71-6. doi: 10.1016/s0939-6411(00)00129-6.

Abstract

The purpose of this study was to define coating conditions for the enteric coating of a highly water soluble, acidic tablet core. Acidic tablet cores containing a marker drug were separated into three groups and seal coated to coverage levels of 0% (uncoated, white), 1% (yellow), and 3% (tan) weight gains. By employing a 'color coding' scheme, the different seal coated tablets could be coated simultaneously to reduce the number of experiments and eliminate potential differences that may exist during separate coating processes. In addition, an allotment of each coded tablet type was sequentially numbered with a marker pen, weighed, and recorded in order to identify the precise level of enteric coating as well as to monitor the variability of a given coating operation. The tablets were coated with five Eudragit((R)) L30D-based enteric formulations containing different amounts of plasticizer (10-20 parts) and talc (10-50 parts). During each enteric coating process, a predetermined amount of labeled tablets were removed after attaining 6, 8, and 10% weight gains. The labeled tablets were re-weighed, sorted, and then tested using USP disintegration and dissolution methods. Weight gain measurements of individual tablets indicated low coating variability (6.2% RSD) during the enteric coating processes. Dissolution results revealed that all enteric coat formulations inhibited drug release for 2 h in 0.1 N HCl. In contrast, it was found that tablets without a seal coat failed the USP disintegration test. In addition, seal coated tablets exhibited ca. 1.5-5 fold greater drug release at most intermediate sampling time points in phosphate buffer, pH 6.8, than tablets without a seal coat, suggesting that the dissolution of the latter was delayed by the generation of an acidic microenvironment at the interface of the enteric coat/acidic tablet core. Prior to enteric coating an acidic, highly water soluble substrate, a seal coat barrier should be applied to prevent retardation in drug release. A simple strategy utilizing color coding and tablet marking can be employed to test the effect of a seal coat, evaluate enteric coating formulations and process with minimal experimentation and analyses.

摘要

本研究的目的是确定一种高水溶性酸性片剂芯材肠溶包衣的包衣条件。将含有标记药物的酸性片剂芯材分为三组,并进行密封包衣,增重分别达到0%(未包衣,白色)、1%(黄色)和3%(棕褐色)。通过采用“颜色编码”方案,可以同时对不同的密封包衣片剂进行包衣,以减少实验次数,并消除单独包衣过程中可能存在的潜在差异。此外,每种编码片剂类型的一部分用记号笔依次编号、称重并记录,以便确定肠溶包衣的精确水平,并监测给定包衣操作的变异性。用五种基于Eudragit((R)) L30D的肠溶制剂对片剂进行包衣,这些制剂含有不同量的增塑剂(10 - 20份)和滑石粉(10 - 50份)。在每次肠溶包衣过程中,在达到6%、8%和10%的增重后,取出预定数量的标记片剂。对标记片剂重新称重、分类,然后使用美国药典(USP)的崩解和溶出方法进行测试。单个片剂的增重测量表明,在肠溶包衣过程中包衣变异性较低(相对标准偏差为6.2%)。溶出结果显示,所有肠溶包衣制剂在0.1 N盐酸中均能抑制药物释放2小时。相比之下,发现没有密封包衣的片剂未通过USP崩解试验。此外,在pH 6.8的磷酸盐缓冲液中,大多数中间取样时间点,密封包衣片剂的药物释放量比没有密封包衣的片剂高约1.5 - 5倍,这表明后者由于肠溶包衣/酸性片剂芯材界面处酸性微环境的产生而延迟了溶解。在对酸性、高水溶性底物进行肠溶包衣之前,应施加密封包衣屏障以防止药物释放延迟。可以采用一种利用颜色编码和片剂标记的简单策略,以最少的实验和分析来测试密封包衣的效果、评估肠溶包衣制剂和工艺。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验